A carregar...
Bevacizumab Treatment to Progression After Chemotherapy: Outcomes from a U.S. Community Practice Network
Bevacizumab significantly extends progression-free survival (PFS) and overall survival (OS) times when combined with initial chemotherapy and continued as monotherapy until disease progression or unacceptable toxicity in patients with nonsquamous non-small cell lung cancer (NSCLC). In clinical pract...
Na minha lista:
| Main Authors: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
AlphaMed Press
2011
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3228113/ https://ncbi.nlm.nih.gov/pubmed/21441299 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2010-0287 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|